The best treatment of CMV gastrointestinal disease has been controversial, with some centers adding intravenous (i. 
Despite improvements in prevention of CMV disease in BMT patients, the outcome of treatment of established CMV disease remains a significant problem after allogeneic BMT. [1] [2] [3] [4] In CMV pneumonia the established practice is to add high-dose (i.v.) immune globulin (i.v. Ig) to antiviral therapy, usually with ganciclovir (GCV). This practice is based on several uncontrolled studies all showing improved outcome compared with historical controls. 1, [5] [6] [7] In CMV Correspondence: Dr P Ljungman, Dept of Hematology, Huddinge University Hospital, Karolinska Institutet, S-14186 Huddinge, Sweden Received 7 May 1997; accepted 28 September 1997 gastrointestinal (GI) disease no study has been performed regarding the need for i.v. Ig in treatment of CMV GI disease. Despite this lack of data, a survey on current treatment practice performed by the Infectious Diseases Working Party of the EBMT showed that 66% of centers added i.v. Ig to antiviral therapy. 8 The aims of this retrospective study were to collect data on outcome of therapy of CMV GI disease with or without the addition of i.v. Ig and to get background information to find out if a prospective randomized trial comparing antiviral therapy with or without i.v. Ig would be feasible.
Methods

Study design
This study was conducted as a retrospective data collection through a questionnaire sent to participating EBMT centers. Fourteen centers responded to the survey (see Acknowledgements). The questionnaire included questions regarding patient characteristics, diagnosis, BMT procedure, diagnosis of CMV GI disease, therapy of CMV GI disease and outcome.
Definition of CMV GI disease
The definition of CMV GI disease followed the recommendations from the 4th International CMV conference. 9 This definition requires the presence of upper or lower GI symptoms in combination with CMV detected in biopsy material from endoscopy of the upper or lower GI tract by histopathology, immunohistochemistry, or DNA hybridization.
Definitions of therapy outcome
The response to therapy was classified according to the following criteria. 
Statistics
Baseline characteristics were compared by Mann-Whitney U-test (two-tailed) or Fisher's exact test. The treatment outcome was scored as response, possible response, or failure as described above. For statistical purposes one patient with a possible response was included among the responding patients. Time to treatment failure was analyzed by the Kaplan-Meier method and survival curves compared by the log-rank test. Finally, a Cox proportional hazards regression model was used to analyze the influence of acute GVHD on outcome.
Results
Thirty-eight patients were included in the study. Five of the patients had simultaneous diagnosis of CMV GI disease and CMV pneumonia and were analyzed separately. The characteristics of the 33 patients without concomitant interstitial pneumonia are shown in Table 1 . There were no significant differences in any of the characteristics.
Therapy for CMV GI disease
Thirty-three patients were treated for CMV GI disease without pneumonia. Twenty-two patients received antiviral therapy without i.v. Ig. Eighteen of these patients received GCV and four patients foscarnet. Eleven patients received the combination of antiviral therapy and i.v. Ig, 10 of whom received GCV and one foscarnet. Five patients were treated with standard i.v. Ig and six patients with CMV hyperimmune globulin. All five patients who had both CMV pneumonia and GI disease were treated with the combination of GCV and i.v. Ig.
Response to therapy
Eighteen of 33 patients (55%) responded to therapy. In addition, one patient had a possible response. The cause of failure was progressive CMV disease with subsequent No. of patients with acute GVHD Grades 0-I 4 1 4 N S Grades II-IV 7 8 NS = non significant. death in eight of 15 patients and death from other causes with ongoing CMV GI disease in seven patients. Thirteen of 22 (59%) patients with CMV GI disease who received antiviral therapy alone responded. The corresponding number for patients who received the combination of antiviral therapy and i.v. Ig was five of 11 (45%; NS, Fisher's exact test). The mean duration of therapy in responding patients was longer (22 days) than in non-responding patients (12 days; P Ͻ 0.01; log-rank test). Fifteen of 28 (54%) patients treated with GCV with or without the addition of i.v. Ig responded to therapy compared to three of five (60%) patients treated with foscarnet. Correspondingly, two of five patients and three of six patients treated with standard or hyperimmune Ig responded, respectively.
There was no statistical difference in outcome between patients receiving or not receiving Ig (Table 2) . Patients with acute GVHD grades II-IV had a significantly worse outcome than patients with acute GVHD grades 0-I. This effect was independent of the use of i.v. Ig as therapy for CMV GI disease. In a Cox model corrected for acute GVHD there was no statistical difference in response with or without the addition of i.v. Ig to antiviral chemotherapy (P = NS). However, due to the small sample size the results of this analysis must be treated with great caution.
Survival
The total survival at 100 days after diagnosis of CMV GI disease was 64%. The probabilities of survival in patients treated with or without the addition of i.v. Ig are shown in Figure 1 .
The causes of death in the responding patients were relapse of CMV disease + GVHD in one patient, another infection in one patient, and relapse of the original disease in one patient. The causes of death in the patients who did Table 2 Response to therapy in patients with and without acute GVHD not respond to therapy were CMV disease alone in four patients, CMV together with GVHD in three patients, GVHD and GI bleeding in one patient, other infections in four patients, ischemic heart disease in one patient, and relapse of original disease in one patient. The causes of death according to therapy groups are given in Table 3 .
Acute GVHD No. of responding patients/total patients Ig group No Ig group
Patients with combination of CMV GI disease and pneumonia
Two of five patients with both CMV GI disease and pneumonia responded to therapy. The survival of these patients at 100 days after diagnosis of CMV GI disease was 20%. 
Discussion
The optimal management of CMV GI disease in BMT patients is not determined. Only one controlled study has been performed comparing GCV 2.5 mg three times daily for 14 days with placebo. 10 This study showed that despite better CMV control in the GCV-treated patients there was no difference in clinical symptoms, endoscopic appearance after therapy, development of CMV pneumonia, or survival. One possible cause for this lack of effectiveness would be that 14 days of therapy is not sufficient to allow healing of lesions in the GI tract. Another possibility is the simultaneous presence of CMV GI disease and acute GVHD of the gut. Based on the lack of effectiveness of GCV alone and the experience with better response rates in therapy of CMV pneumonia with the addition of CMV GI disease, many BMT centers have prolonged the duration of the antiviral therapy and some centers have also added high-dose i.v. Ig to the treatment regimen. The reason for the better results of therapy in CMV pneumonia with the combination of GCV and i.v. Ig is poorly understood. It has been speculated that it could be due to immunomodulation rather than direct antiviral effect eventually due to anti-cytokine effects. Furthermore, the initial very favorable results of the addition of i.v. Ig reported in the early studies have not been reproduced in recent years. 1, 3 In a study by the EBMT 30 day survival was only 31%. 1 Similar survival figures in a large series of patients from the Seattle group have recently been presented by Boeckh et al. 11 The present study has limitations that reduce the possi-bility of drawing firm conclusions. First, it is a retrospective collection of cases and not a prospective randomized trial. Second, the therapy protocols varied between the participating centers. Third, in most cases post-therapy endoscopies to objectively assess outcome were not performed. However, we believe that we can get some suggestions from the results that might be useful for future management of BMT patients with CMV GI disease. The primary aim of the study was to determine if the addition of i.v. Ig to antiviral therapy would improve treatment results. The complete lack of any tendency for a benefit of Ig strongly contradict any such major effect. It could be argued that this lack of beneficial effect was caused by an imbalance of risk factors between the two groups in a way that the patients who were at higher risk for CMV disease would be more likely to get the addition of i.v. Ig and therefore the combination would be at a disadvantage for showing a benefit.
However, the most important risk factor for CMV disease is acute GVHD of grades II-IV. 12, 13 This is supported by our survey since 54% of patients had acute GVHD of grades II-IV. It was also commented in histopathology reports that in many patients GVHD and CMV were simultaneously present in the biopsies. However, there was no significant difference between the two therapy groups in the proportion of patients with acute GVHD. Moreover, when adjusted for acute GVHD in a Cox proportional hazards model, there was still no advantage for the use of i.v. Ig. It could also be argued that the treating physicians added Ig for the patients with more severe disease and thereby unbalanced the groups, but in fact the treatment policies were consistent in the majority of centers.
Thus, we could find no differences in either response rates or survival with or without the addition of high-dose i.v. Ig to antiviral therapy for CMV GI disease. Therefore, despite the limitations of a non-controlled study, our study strongly suggests that i.v. Ig is not indicated in CMV GI disease without pneumonia. Furthermore, with the low number of reported cases, the increased use of preemptive therapy for CMV antigenemia or detection of DNA which reduce the risk for CMV disease, and the results of our study, a randomized trial of the addition of i.v. Ig is not feasible and probably not necessary.
